A substantial number of G-protein-coupled receptor-interacting proteins have been identified initially by the use of yeast two-hybrid screens. Using the C-terminal tail of both opioid receptors and the melanin concentrating hormone receptor-1 as bait, the actin and intermediate filament-binding protein periplakin was isolated. In each case, the site of interaction is within helix VIII of the receptor and periplakin limits agonist-mediated G-protein activation potentially by competing with G-protein for this region of the receptor.
Introduction
Although initially considered to exist in isolation as monomers, recent studies have shown that GPCRs (G-proteincoupled receptors) often exist within macromolecular complexes [1] [2] [3] . In addition to the quaternary structure provided through GPCR homo-and heterodimerization [4, 5] , a large number of GPCR-interacting proteins have been identified. Trivial examples include both heterotrimeric G-proteins and arrestins that play key roles in the generation and termination of GPCR-mediated signals. Models and predictions of the interactions between GPCRs and both G-proteins [6, 7] and arrestins [8] indicate that the GPCR dimer provides an appropriate footprint to bind a single heterotrimeric G-protein or arrestin. This implies that there are multiple contact points between a GPCR dimer and these interacting proteins and it provides an explanation of why interactions of a GPCR dimer with an arrestin and a G-protein are mutually exclusive. For protein-protein interactions that require a series of complex interactions, each interaction in isolation is presumably of relatively low affinity. In contrast, analysis of sequences of GPCRs has frequently allowed identification of previously defined protein-protein interaction domains consisting of short linear sections of the GPCR primary structure that allow high-affinity interactions with specific protein partners [9] . For example, sequences located at the extreme C-terminal tail of a number of GPCRs, including the β 1 - [10] and β 2 -adrenoceptors [11, 12] and the 5-hydroxytryptamine 5-HT 2A [13] and 5-HT 2C receptors [13, 14] inhibitory motif in the C-terminal tail of the bradykinin B2 receptor allows interactions with the phosphatase SHP-2 [17] . Complex protein networks can then be established based on protein-protein interaction motifs within the GPCRinteracting proteins [18, 19] .
Many other GPCR-interacting proteins have been identified without a priori knowledge of probable proteinbinding motifs. Such studies have employed a range of approaches but the two most widely applied are proteomics [20] and yeast two-hybrid screens [21] . Proteomic studies based on analysis of polypeptides associated with GPCRs after immunoprecipitation or purification methods have the distinct advantage of being inherently non-biased. However, they are often limited by the poor availability of antisera capable of immunoprecipitating GPCRs effectively and efficiently from native tissues. Similarly, low levels of expression of many GPCRs in native tissues makes analysis and identification of co-purified or co-precipitated proteins a challenging task. Despite this, impressive progress has been made [13, 14] . However, at least to date, yeast two-hybrid screens have provided the starting point for most of the studies. As polypeptides with a complex transmembrane topology, the seven transmembrane architecture of GPCRs makes them inherently unsuitable to act as a bait in yeast two-hybrid screens. However, many GPCRs have substantial extracellular N-terminal and intracellular C-terminal domains and many of them also have a long third intracellular loop. The intracellular elements are hydrophillic and soluble and can thus be used as a bait in yeast two-hybrid screens. This approach is unlikely to identify GPCR-interacting proteins such as G-proteins and arrestins that interact with a series of elements that are non-contiguous within the GPCR primary sequence. However, it has been used to identify a considerable range of potential GPCR-interacting proteins that presumably interact with the (generally unknown) structure provided by a linear sequence segment of a GPCR.
Interactions between opioid receptors and periplakin
On the basis of the premise outlined above, we used the sequence corresponding to the intracellular C-terminal tail of the human MOP-1 opioid receptor as the bait in a yeast twohybrid screen to identify interacting proteins encoded within a human brain cDNA library [22] . Sequencing of multiple positive clones resulted in the identification of periplakin [23] [24] [25] . Periplakin is a 1756 amino acid polypeptide but all of the hits in the yeast two-hybrid screen contained the extreme C-terminal linker region of this protein and/or the C-terminal section of the adjacent rod domain. Analysis of this region of periplakin suggests the presence of approx. 100 amino acids of strongly predicted coiled-coil followed by 100 amino acids containing two plectin repeats. Interestingly, this is the region of periplakin that has also been shown to be involved in interactions with the intermediate filament proteins keratin and vimentin [26, 27] and as a binding partner for protein kinase B [28] . Interaction was also observed between periplakin and the MOP-1A opioid receptor splice variant [22] . This variant differs in sequence from MOP-1 only at the extreme C-terminus and these results eliminated the possibility that interaction was defined by this region. Use of fragments of the MOP-1 opioid receptor C-terminal tail as bait indicated the interaction site to be provided by a region proximal to the plasma membrane at the end of transmembrane helix VII [22] . Pull-down assays using GST fusions of segments of the receptor C-terminal tail and a Histagged form of the C-terminal 208 amino acids of periplakin (PPLC) confirmed interactions and, as expected from the above, a GST fusion protein incorporating the MOP-1 C-terminal linked to green fluorescent protein also captured His-PPLC [22] .
Periplakin is best studied as a key polypeptide involved in the production of the cornified epithelium of the skin [26, 27] . However, by using both immunoblotting and quantitative reverse transcriptase-PCR, we demonstrated it to be both widely and highly expressed in various regions of both rodent and human brain [22] . However, it was not expressed to detectable levels in commonly used neuronal cell lines, such as SHSY5Y neuroblastoma and NG108-15 neuroblastoma x glioma cells. It was also not expressed to immunodetectable levels in HEK-293 cells (human embryonic kidney 293 cells) [22] . HEK-293 cells thus acted as host to explore the functional consequences of interactions between the MOP-1 receptor and periplakin. Synthetic peptide agonists of the MOP-1 receptor, such as DAMGO ([D-Ala 2 , N-Me-Phe 4 , Gly 5 -ol]enkephalin), are capable of producing extensive internalization of the receptor. This was monitored after transient expression of a full-length MOP-1 receptor tagged at the C-terminus with green fluorescent protein. Co-expression of full-length periplakin did not interfere with DAMGO-induced internalization. Similar results were obtained when cell-surface MOP-1 receptors were identified by biotinylation. DAMGO treatment removed the receptor from the cell surface and this was not blocked by coexpression of periplakin.
The delineated site of interaction of periplakin within the MOP-1 receptor corresponds to the so-called 'fourth intracellular loop'. The atomic level structure of bovine rhodopsin [29] indicates that the equivalent region forms a helix that runs parallel to the plasma membrane and is concluded by a pair of thioacylated cysteine residues, where insertion of the fatty acyl chains into the lipid bilayer provides a point of anchorage [30] . As this region is known to provide a contact region for G-protein α-subunits [31] , we then investigated whether periplakin would interfere with MOP-1 receptor-mediated G-protein activation. A routine finding after co-expression of MOP-1 receptor and periplakin was that expression of [ 3 H]antagonist-binding sites corresponding to the MOP-1 receptor were reduced substantially compared with expression without periplakin. To ensure that this was not responsible for the data obtained, we expressed a fusion protein between the MOP-1 receptor and a pertussis toxin-resistant variant of the G-protein Gα i1 with and without periplakin. GPCR-G-protein fusions ensure that a defined 1:1 stoichiometry of receptor to Gprotein is maintained, irrespective of the absolute level of expression [32, 33] . Opioid receptors interact selectively with members of the G i -family of G-proteins. Use of a pertussis toxin-resistant variant of Gα i1 , which we had previously established to be activated effectively by the MOP-1 receptor [34] , meant that cells expressing this construct could be treated with pertussis toxin to prevent contacts between constructs and endogenously expressed forms of G i . This ensured that signals produced had to reflect activation of the receptor-linked G-protein. When membranes expressing equal amount of the MOP-1-Gα i1 fusion protein were used to measure agonist-mediated G-protein activation, the presence of periplakin substantially reduced DAMGO-stimulated [
35 S]GTP[S] binding [22] .
Interactions between periplakin and the MCH-1 (melanin concentrating hormone-1) receptor
As part of a wider screen for GPCRs that interact with periplakin, we identified the MCH-1 receptor [35] [36] [37] . This receptor has attracted considerable attention as a possible target for therapeutic intervention in obesity because, in mice, inactivation of the genes encoding either this receptor [38] or the peptide MCH [39] results in a lean phenotype and a resistance to diet-induced obesity. Both pull-down studies employing recombinantly expressed forms of the C-terminal tail of this receptor and PPLC and co-immunoprecipitation studies after co-expression of the full-length MCH-1 receptor and PPLC confirmed such interactions. As with the MOP-1 receptor, truncation from the C-terminal tail of the MCH-1 receptor indicated interactions to be provided through a segment proximal to transmembrane helix VII. Deletion of two separate five amino acid segments of this region eliminated interaction. Unlike most rhodopsin-family GPCRs, the MCH-1 receptor does not have one or more cysteine residues in the C-terminal tail, which are probably targets for post-translational thioacylation. However, the region we identified as the periplakin-binding domain is concluded on the C-terminal side by a proline residue that may act to terminate 'helix' VIII. As with the MOP-1 receptor, coexpression of periplakin did not interfere with agonistinduced internalization of the MCH-1 receptor. However, again, co-expression with periplakin in HEK-293 cells resulted in a large reduction in the ability of MCH to induce binding of [ 35 S]GTPγ S to a pertussis toxin-resistant form of Gα o1 . A recent study [40] has indicated that mutation of either Arg 319 , Lys 320 or both these amino acids in the rat MCH-1 receptor results in reduced agonist-mediated increase in [Ca 2+ ] i . These residues correspond to the arginine and lysine residues within the 316-ETFRK-320 segment of the human MCH-1 receptor, which when eliminated results in loss of periplakin binding. Combination of these observations provides a strong rational for the concept that periplakin functions to reduce MCH-mediated signal transduction by competing with G-protein for binding to the receptor.
Future directions
Studies conducted in parallel have indicated that the interaction of GPCRs with periplakin is selective. Based on the combinations of yeast two-hybrid screens, pull-down and co-immunoprecipitation studies, we observed no interactions of periplakin with a range of GPCRs, including the α 2A -and β 2 -adrenoceptors [22] and the IP prostanoid receptor. Not surprisingly, therefore, co-expression of periplakin with these receptors does not inhibit G-protein activation and signal initiation. In humans, the non-olfactory rhodopsinlike, class A GPCRs are produced from a family of some 300 genes, and although a comprehensive screen for interactions is unlikely to be achieved, analysis of potential interactions with a significant number of GPCRs will help to define the basis for the interaction. Similarly, the capacity to produce and purify good levels of PPLC in recombinant systems and to define the interaction site within certain GPCRs to a short, linear peptide sequence will allow efforts to determine directly the structural basis of these interactions employing either or both crystallography and NMR.
Physiological roles of periplakin in the regulation of GPCR function may also be analysed, as knockout mouse models become available and the results produced to date suggest that periplakin-interacting GPCRs may function more effectively in the absence of this polypeptide. Equally, as periplakin is already recognized as an actin and intermediate filamentbinding protein [26, 27] , it may well provide a means to scaffold GPCRs into multi-molecular complexes that can be analysed through proteomic techniques.
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